1. Pink Sheet
  2. >>Biosimilars & Generics
  3. >>Generics

New AAM CEO: Traditional Lobbying On Lowering Health Care Costs Can Mix With COVID-19 Talks

 
• By Derrick Gingery

Dan Leonard is working on post-pandemic generic drug issues, using coronavirus as a way to get in front of lawmakers.

3D render of generic pill with granules over white background - Illustration
New AAM President and CEO Dan Leonard wants generics sponsors to be proud of their work maintaining the supply chain during the pandemic. • Source: Shutterstock

New Association for Accessible Medicines president and CEO Dan Leonard is using coronavirus issues to push the generics industry’s non-pandemic priorities to policymakers.

More pandemic relief appears to be the primary focus of Capitol Hill now that the election is nearing its conclusion, but in an interview with the Pink Sheet, Leonard said restarting a

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

Pharma Industry Argues Tax, Other Incentives Better Than Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a federal 232 investigation.

US FDA Guidance Roadblock: Writing Continues, But Publication Has Slowed Or Stopped

 
• By Derrick Gingery

Cuts to the FDA’s policy and legal personnel have prevented dozens of product-specific guidances for generic drug development from being published.

Viatris Agrees To $335m Opioid Settlement Ending US State, Local Government Cases

 
• By Dean Rudge

Viatris joined Hikma and Amneal, in signing agreements for cash settlements that resolve allegations its practices fueled the US’ deadly opioid epidemic.

US FDA Shows Support For Generic Drug User Fee Goals Amid Cutbacks

 
• By Michael McCaughan

The FDA struck an upbeat tone during its annual Generic Drugs Forum despite an unprecedented period of cutbacks and disruptions and reiterated a desire to continue meeting user fee goals.

More from Biosimilars & Generics